Anzeige
Mehr »
Login
Montag, 29.11.2021 Börsentäglich über 12.000 News von 683 internationalen Medien
Rücksetzer eröffnet geniale Kaufchance bei ETHEREUM! Gebührenfreier ETN von Valour macht Spaß!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 924801 ISIN: US09061G1013 Ticker-Symbol: BM8 
Tradegate
26.11.21
21:58 Uhr
75,26 Euro
-0,18
-0,24 %
1-Jahres-Chart
BIOMARIN PHARMACEUTICAL INC Chart 1 Jahr
5-Tage-Chart
BIOMARIN PHARMACEUTICAL INC 5-Tage-Chart
RealtimeGeldBriefZeit
77,0677,5407:06
75,2675,6026.11.

Aktuelle News zur BIOMARIN PHARMACEUTICAL Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
BIOMARIN PHARMACEUTICAL Aktie jetzt für 0€ handeln
MiHopeful Golden Cross Forms On Biomarin Pharmaceutical's Chart3
MiBiotech Stock Roundup: Drug Approvals for BMRN, Updates From BIIB, BMY, MRNA & More31
22.11.BioMarin's (BMRN) Dwarfism Drug Gets FDA's Nod, Stock Up3
22.11.BioMarin Pharma upgraded to Outperform at William Blair after FDA approval of Voxzogo9
21.11.BioMarin Pharma sees big things for first FDA-approved dwarfism drug11
20.11.Why BioMarin Pharmaceutical Stock Jumped by 10.3% on Friday8
19.11.FDA Approves BioMarin's Drug To Treat Dwarfism764WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) Friday said that the U.S. Food and Drug Administration has granted accelerated approval to Voxzogo, the first drug approved by the...
► Artikel lesen
19.11.BioMarin drug becomes first US approved therapy for dwarfism7
19.11.BioMarin wins FDA approval for injection to increase growth in children with dwarfism3
19.11.BioMarin wins first US drug approval for common type of dwarfism3
19.11.BioMarin's dwarfism drug Voxzogo could be its next blockbuster, but ethics questions loom over the launch8
19.11.US FDA approves BioMarin's drug for a type of dwarfism5
19.11.BioMarin says US FDA approves its drug for a type of dwarfism5
15.11.BioMarin's new launch Voxzogo could surprise investors and become a blockbuster brand: analyst10
14.11.The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More8
12.11.NICE 'no' for BioMarin's Vimizin4
01.11.Jensen: BioMarin Is a Synthetic Dividend Play11
01.11.BioMarin: Voxzogo Approval Could Trigger A Lengthy Bull Run For Cash Rich Biotech8
29.10.BIOMARIN PHARMACEUTICAL INC - 10-Q, Quaterly Report4
28.10.BioMarin (BMRN) Beats on Q3 Earnings, Ups 2021 Guidance19
Seite:  Weiter >>
86 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2